Cholangiocarcinoma  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

14 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00338988: Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

Completed
2
44
US
Capecitabine, Xeloda, Oxaliplatin, Eloxatin
M.D. Anderson Cancer Center, Sanofi-Synthelabo
Cancer of the Gallbladder, Cancer of the Biliary Tract
05/09
05/09
NCT00552149 / 2007-001200-20: Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Checkmark
May 2014 - May 2014: 
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 data - ASCO
More
Completed
2
150
Europe
Gemox, Cetuximab
Gustave Roussy, Cancer Campus, Grand Paris, Merck Serono International SA
Advanced Biliary Cancer
04/12
04/12
NCT03486678: SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Completed
2
38
RoW
SHR-1210+GEMOX
The First Affiliated Hospital with Nanjing Medical University, Jiangsu HengRui Medicine Co., Ltd.
Biliary Tract Cancer, Cholangiocarcinoma
08/20
11/20
QLYY-iCCA-01, NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
25
RoW
HAIC+TAE, Tislelizumab, Surufatinib
Qilu Hospital of Shandong University, BeiGene
Intrahepatic Cholangiocarcinoma
05/24
12/25
NCT06208462: Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
33
RoW
Adebrelimab, SHR-1316, Lenvatinib, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Gemcitabine, Difluorodeoxycytidine Hydrochloride, Oxaliplatin, Diaminocyclohexane Oxalatoplatinum
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Intrahepatic Cholangiocarcinoma
01/26
01/27
CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
36
RoW
HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab
Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer
Cholangiocarcinoma Non-resectable
12/25
06/26
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
11/25
10/26
BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting
2
80
Europe, US
LSTA1, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo
Lisata Therapeutics, Inc.
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
12/25
12/25
KEYVIBE-005, NCT05007106 / 2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

Recruiting
2
610
Europe, Canada, Japan, US, RoW
Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, Lenvima, E7080, MK-7902, 5-Fluorouracil, 5-FU, Fluracil, Cisplatin, Platinol, cis Platinum, Paclitaxel, Taxol, Abraxane, Anzatax, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
02/27
02/27
2013-004385-34: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial

Not yet recruiting
1/2
87
Europe
Coated tablet, Powder for solution for infusion, STIVARGA, GEMCITABINE, OXALIPLATINE
Institut régional du Cancer - Montpellier - Val d'Aurelle, Institut régional du Cancer - Montpellier - Val d'Aurelle
advanced Biliary Tract Cancer, Biliary Cancer, Diseases [C] - Cancer [C04]
 
 
NCT02024607: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO-GI
Jan 2016 - Jan 2016: ASCO-GI
Checkmark ASCO-GI 2016
More
Completed
1/2
495
Canada, US
BBI608, Napabucasin, BB608, BBI-608, Fluorouracil, 5-FU, Carac, Efudex, Fluoroplex, Adrucil, Oxaliplatin, Eloxatin, Leucovorin, Folinic Acid, Irinotecan, Camptosar, Bevacizumab, Avastin, Capecitabine, Xeloda, Regorafenib, Stivarga
Sumitomo Pharma America, Inc.
Advanced Gastrointestinal Cancer
03/19
11/19
NCT05116891: A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed
1/2
40
Europe
CAN04 (nadunolimab), nadumolimab, mFOLFOX, Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin, DTX, Docetaxel, G/C, Gemcitabine and cisplatin
Cantargia AB
Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer
06/23
06/23
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
08/24
11/24
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
03/25
10/25

Download Options